Publications

Biosciences

The Anopheles coluzzii range extends into Kenya: detection, insecticide resistance profiles and population genetic structure in relation to conspecific populations in West and Central Africa.Kamau, L. Bennett, K. L. Ochomo, E. Herren, J. Agumba, S. Otieno, S. Omoke, D. Matoke-Muhia, D. Mburu, D. Mwangangi, J. Ramaita, E. Juma, E. O. Mbogo, C. Barasa, S. Miles, A.
Malar J, (2024). 23:122

Bi-isotype immunoglobulins enhance antibody-mediated neutrophil activity against Plasmodium falciparum parasites.Ogwang, R. Murugu, L. Nkumama, I. N. Nyamako, L. Kai, O. Mwai, K. Murungi, L. Idro, R. Bejon, P. Tuju, J. Kinyanjui, S. M. Osier, F. H. A.
Front Immunol, (2024). 15:1360220

Editorial: Malaria molecular epidemiology current situation in Africa.Tandoh, K. Z. Duah-Quashie, N. O. Raman, J. Ochola-Oyier, L. I.
Front Epidemiol, (2024). 4:1400612

Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.Asante, K. P. Mathanga, D. P. Milligan, P. Akech, S. Oduro, A. Mwapasa, V. Moore, K. A. Kwambai, T. K. Hamel, M. J. Gyan, T. Westercamp, N. Kapito-Tembo, A. Njuguna, P. Ansong, D. Kariuki, S. Mvalo, T. Snell, P. Schellenberg, D. Welega, P. Otieno, L. Chimala, A. Afari, E. A. Bejon, P. Maleta, K. Agbenyega, T. Snow, R. W. Zulu, M. Chinkhumba, J. Samuels, A. M. Malaria Vaccine Programme Evaluation, Partners
Lancet, (2024). 403:1660-1670

Age-dependent acquisition of IgG antibodies to Shigella serotypes-a retrospective analysis of seroprevalence in Kenyan children with implications for infant vaccination.Kapulu, M. C. Muthumbi, E. Otieno, E. Rossi, O. Ferruzzi, P. Necchi, F. Acquaviva, A. Martin, L. B. Orindi, B. Mwai, K. Kibet, H. Mwanzu, A. Bigogo, G. M. Verani, J. R. Mbae, C. Nyundo, C. Agoti, C. N. Nakakana, U. N. Conti, V. Bejon, P. Kariuki, S. Scott, J. A. G. Micoli, F. Podda, A.
Front Immunol, (2024). 15:1340425

Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.Kapulu, M. Manda-Taylor, L. Balasingam, S. Means, G. Ayiro Malungu, M. Bejon, P. Chi, P. C. Chiu, C. Church, E. C. Correa-Oliveira, R. Day, N. Durbin, A. Egesa, M. Emerson, C. Jambo, K. Mathur, R. Metzger, W. Mumba, N. Nazziwa, W. Olotu, A. Rodgers, J. Sinyiza, F. Talaat, K. Kamerling, I. Weller, C. Baay, M. Neels, P.
Biologicals, (2024). 85:101747

Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023.Cavaleri, M. Kaslow, D. Boateng, E. Chen, W. H. Chiu, C. Choy, R. K. M. Correa-Oliveira, R. Durbin, A. Egesa, M. Gibani, M. Kapulu, M. Katindi, M. Olotu, A. Pongsuwan, P. Simuyandi, M. Speder, B. Talaat, K. R. Weller, C. Wills, B. Baay, M. Balasingam, S. Olesen, O. F. Neels, P.
Biologicals, (2024). 85:101745

Accumulating evidence on the long-term immunogenicity of fractional dosing for yellow fever vaccines.Juan-Giner, A. Warimwe, G.
Lancet Infect Dis, (2024). 24:562-564

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.Datoo, M. S. Dicko, A. Tinto, H. Ouedraogo, J. B. Hamaluba, M. Olotu, A. Beaumont, E. Ramos Lopez, F. Natama, H. M. Weston, S. Chemba, M. Compaore, Y. D. Issiaka, D. Salou, D. Some, A. M. Omenda, S. Lawrie, A. Bejon, P. Rao, H. Chandramohan, D. Roberts, R. Bharati, S. Stockdale, L. Gairola, S. Greenwood, B. M. Ewer, K. J. Bradley, J. Kulkarni, P. S. Shaligram, U. Hill, A. V. S. R. 1/Matrix-M Phase 3 Trial Group
Lancet, (2024). 403:533-544

Distinct transcriptomic signatures define febrile malaria depending on initial infective states, asymptomatic or uninfected.Kimenyi, K. M. Akinyi, M. Y. Mwikali, K. Gilmore, T. Mwangi, S. Omer, E. Gichuki, B. Wambua, J. Njunge, J. Obiero, G. Bejon, P. Langhorne, J. Abdi, A. Ochola-Oyier, L. I.
BMC Infect Dis, (2024). 24:140

Sugar and blood: the nutritional priorities of the dengue vector, Aedes aegypti.Tenywa, F. C. Musa, J. J. Musiba, R. M. Swai, J. K. Mpelepele, A. B. Okumu, F. O. Maia, M. F.
Parasit Vectors, (2024). 17:26

Controlled Human Malaria Infection Studies in Africa-Past, Present, and Future.Kibwana, E. Kapulu, M. Bejon, P.
Curr Top Microbiol Immunol, (2024). 445:337-365

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.Kimotho, J. Sein, Y. Sayed, S. Shah, R. Mwai, K. Saleh, M. Wanjiku, P. Mwacharo, J. Nyagwange, J. Karanja, H. Kutima, B. Gitonga, J. N. Mugo, D. Karanu, A. Moranga, L. Oluoch, V. Shah, J. Mutiso, J. Mburu, A. Nneka, Z. Betti, P. Usyu Mutinda, W. Issak Abdi, A. Bejon, P. Isabella Ochola-Oyier, L. M. Warimwe G Nduati, E. W. M. Ndungu F
Wellcome Open Res, (2023). 8:350

Utility of MALDI-TOF MS for determination of species identity and blood meal sources of primary malaria vectors on the Kenyan coast.Karisa, J. Ominde, K. Tuwei, M. Bartilol, B. Ondieki, Z. Musani, H. Wanjiku, C. Mwikali, K. Babu, L. Rono, M. Eminov, M. Mbogo, C. Bejon, P. Mwangangi, J. Laroche, M. Maia, M.
Wellcome Open Res, (2023). 8:151

Safety and immunogenicity of varied doses of R21/Matrix-M vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.Sang, S. Datoo, M. S. Otieno, E. Muiruri, C. Bellamy, D. Gathuri, E. Ngoto, O. Musembi, J. Provstgaard-Morys, S. Stockdale, L. Aboagye, J. Woods, D. Lawrie, A. Roberts, R. Keter, K. Kimani, D. Ndungu, F. Kapulu, M. Njau, I. Orindi, B. Ewer, K. J. Hill, A. V. S. Bejon, P. Hamaluba, M.
Wellcome Open Res, (2023). 8:450

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.Hamaluba, M. Sang, S. Orindi, B. Njau, I. Karanja, H. Kamau, N. Gitonga, J. N. Mugo, D. Wright, D. Nyagwange, J. Kutima, B. Omuoyo, D. Mwatasa, M. Ngetsa, C. Agoti, C. Cheruiyot, S. Nyaguara, A. Munene, M. Mturi, N. Oloo, E. Ochola-Oyier, L. Mumba, N. Mauncho, C. Namayi, R. Davies, A. Tsofa, B. Nduati, E. W. Aliyan, N. Kasera, K. Etyang, A. Boyd, A. Hill, A. Gilbert, S. Douglas, A. Pollard, A. Bejon, P. Lambe, T. Warimwe, G. C. O. V. Vaccine Trial Group
Wellcome Open Res, (2023). 8:182

Low frequency of Plasmodium falciparum hrp2/3 deletions from symptomatic infections at a primary healthcare facility in Kilifi, Kenya.Okanda, D. Ndwiga, L. Osoti, V. Achieng, N. Wambua, J. Ngetsa, C. Lubell-Doughtie, P. Shankar, A. Bejon, P. Ochola-Oyier, L. I.
Front Epidemiol, (2023). 3:1083114

Exposure to common infections may shape basal immunity and potentially HIV-1 acquisition amongst a high-risk population in Coastal Kenya.Fwambah, L. Andisi, C. Streatfield, C. Bromell, R. Hare, J. Esbjornsson, J. Ndung'u, T. Sanders, E. J. Hassan, A. S. Nduati, E.
Front Immunol, (2023). 14:1283559

A metabolic perspective of the neutrophil life cycle: new avenues in immunometabolism.Thind, M. K. Uhlig, H. H. Glogauer, M. Palaniyar, N. Bourdon, C. Gwela, A. Lancioni, C. L. Berkley, J. A. Bandsma, R. H. J. Farooqui, A.
Front Immunol, (2023). 14:1334205

Where do those data go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya.Downs, L. O. Campbell, C. Abouyannis, M. Otiende, M. Kapulu, M. Obiero, C. W. Hamaluba, M. Ngetsa, C. Andersson, M. I. Githinji, G. Warimwe, G. Baisley, K. Scott, J. A. G. Matthews, P. C. Etyang, A.
J Virus Erad, (2023). 9:100355